KURA - Kura Oncology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
17.70
-0.21 (-1.17%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close17.91
Open18.11
Bid0.00 x 900
Ask0.00 x 1300
Day's Range17.48 - 18.10
52 Week Range10.20 - 21.42
Volume199,182
Avg. Volume368,043
Market Cap800.304M
Beta (3Y Monthly)2.05
PE Ratio (TTM)N/A
EPS (TTM)-1.57
Earnings DateAug 9, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.29
Trade prices are not sourced from all markets
  • GlobeNewswire9 days ago

    Kura Oncology Announces Appointment of Kathleen Ford as Chief Operating Officer

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of Kathleen Ford as Chief Operating Officer, effective immediately. Ms. Ford replaces John Farnam, who is stepping down from his position to pursue other interests. “We are very fortunate to have recruited an operations veteran with Kathy’s experience to Kura at a time when strategic prioritization and operational execution are among our highest priorities,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

  • GlobeNewswire14 days ago

    Kura Oncology to Present at Wedbush PacGrow Healthcare Conference

    SAN DIEGO, Aug. 07, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the.

  • Thomson Reuters StreetEvents16 days ago

    Edited Transcript of KURA earnings conference call or presentation 1-Aug-19 8:30pm GMT

    Q2 2019 Kura Oncology Inc Earnings Call

  • Kura Oncology, Inc. (KURA) 2019 Q2 Earnings Call Transcript
    Motley Fool18 days ago

    Kura Oncology, Inc. (KURA) 2019 Q2 Earnings Call Transcript

    KURA earnings call for the period ending June 30, 2019.

  • GlobeNewswire27 days ago

    Kura Oncology to Report Second Quarter 2019 Financial Results

    SAN DIEGO, July 25, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment.

  • GlobeNewswire28 days ago

    Kura Oncology’s Menin-MLL Inhibitor KO-539 Receives Orphan Drug Designation from FDA for Treatment of Acute Myeloid Leukemia

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the Company’s menin-mixed lineage leukemia (menin-MLL) inhibitor KO-539 for the treatment of acute myeloid leukemia (AML). “Orphan Drug Designation for AML represents a significant milestone in the development of KO-539,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

  • GlobeNewswirelast month

    Kura Oncology Expands Protection for Tipifarnib with New U.S. and European Patents

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the U.S. Patent and Trademark Office (USPTO) has issued and the European Patent Office has granted new patents further protecting the Company's lead drug candidate, tipifarnib, a potent and selective farnesyl transferase inhibitor. Tipifarnib is currently being studied in multiple solid tumor and hematologic indications, including a registration-directed clinical trial in HRAS mutant head and neck squamous cell carcinoma (HNSCC).

  • Kura Oncology, Inc. (KURA) Shares March Higher, Can It Continue?
    Zacks2 months ago

    Kura Oncology, Inc. (KURA) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Kura Oncology, Inc. (KURA).

  • Do Insiders Own Shares In Kura Oncology, Inc. (NASDAQ:KURA)?
    Simply Wall St.2 months ago

    Do Insiders Own Shares In Kura Oncology, Inc. (NASDAQ:KURA)?

    A look at the shareholders of Kura Oncology, Inc. (NASDAQ:KURA) can tell us which group is most powerful. Institutions...

  • What Kind Of Investor Owns Most Of Kura Oncology, Inc. (NASDAQ:KURA)?
    Simply Wall St.2 months ago

    What Kind Of Investor Owns Most Of Kura Oncology, Inc. (NASDAQ:KURA)?

    The big shareholder groups in Kura Oncology, Inc. (NASDAQ:KURA) have power over the company. Insiders often own a...

  • GlobeNewswire2 months ago

    Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 885,000 shares at the public offering price of $17.00 per share. SVB Leerink and Cowen acted as joint book-running managers for the offering. The securities described above were offered by Kura pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Kura with the Securities and Exchange Commission (the “SEC”) and that was declared effective on November 21, 2018.

  • GlobeNewswire2 months ago

    Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the pricing of an underwritten public offering of 5,900,000 shares of its common stock at a price to the public of $17.00 per share.  Kura has granted the underwriters a 30-day option to purchase up to an additional 885,000 shares of its common stock. The gross proceeds to Kura from the offering, excluding any exercise by the underwriters of their 30-day option to purchase additional shares, are expected to be $100.3 million, before deducting underwriting discounts and commissions and other offering expenses payable by Kura. SVB Leerink and Cowen are acting as joint book-running managers for the offering.  Wedbush PacGrow and Oppenheimer & Co. are acting as co-lead managers, and H.C. Wainwright & Co. is acting as co-manager for the offering.

  • GlobeNewswire2 months ago

    Kura Oncology Announces Commencement of Public Offering of Common Stock

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock.  In connection with the offering, Kura expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.  There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. SVB Leerink and Cowen are acting as joint book-running managers in the offering. The securities described above are being offered by Kura pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Kura with the Securities and Exchange Commission (the “SEC”) and that was declared effective on November 21, 2018.  A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC’s website located at http://www.sec.gov.  Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering, when available, may be obtained from SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext.

  • Is Kura Oncology, Inc. (KURA) A Good Stock To Buy?
    Insider Monkey2 months ago

    Is Kura Oncology, Inc. (KURA) A Good Stock To Buy?

    "Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]

  • Company News For Jun 17, 2019
    Zacks2 months ago

    Company News For Jun 17, 2019

    Companies In The News Are: FB,BXG,ARQL,KURA

  • TheStreet.com2 months ago

    Kura Oncology Soars After Lymphoma Treatment Test Results

    climbed 6.6% to $19.71 Friday after the clinical-stage biopharmaceutical company said a phase 2 trial of its lymphoma treatment tipifarnib showed encouraging results and achieved its primary endpoint. The San Diego-based company said the results demonstrate ongoing anti-tumor activity and a manageable safety profile in advanced patients with angioimmunoblastic T-cell lymphoma (AITL) as well as non-AITL peripheral T-cell lymphoma (PTCL). "With additional follow up and new patients enrolled in the ongoing Phase 2 study, tipifarnib continues to demonstrate encouraging clinical activity in patients with relapsed or refractory PTCL who have experienced a median of three prior lines of therapy," Francine Foss, professor of medicine at the Yale Cancer Center, and a principal investigator in the trial, said in a statement.

  • MarketWatch2 months ago

    Kura Oncology's stock soars toward record high after trial of lymphoma treatment achieves goal

    Shares of Kura Oncology Inc. soared 27% toward a record high in premarket trading Friday, after the biopharmaceutical company announced a phase 2 trial of its lymphoma treatment achieved its primary efficacy endpoint. The stock was on track to open above its March 2, 2018 record close of $23.40. The company said the results of the trial demonstrated "ongoing anti-tumor activity and a manageable safety profile" in advanced patients with angioimmunoblastic T-cell lymphoma (AITL), as well as non-AITL relapsed or refractory peripheral T-cell lymphoma (PTCL). "We believe these data support the potential to register tipifarnib in both the AITL and PTCL-NOS patient populations, and we look forward to seeking regulatory feedback on next steps for this program," said Chief Executive Troy Wilson. The stock has run up 32% year to date through Thursday, while the iShares Nasdaq Biotechnology ETF has gained 8% and the S&P 500 has advanced 15%.

  • GlobeNewswire2 months ago

    Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in Peripheral T-Cell Lymphoma

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced updated interim data from the ongoing Phase 2 clinical trial of its lead drug candidate, tipifarnib, in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The results, which will be presented during an oral session at 16:45 CET / 10:45 am ET tomorrow at the European Hematology Association (EHA) Annual Congress in Amsterdam, demonstrate ongoing anti-tumor activity and a manageable safety profile in advanced patients with angioimmunoblastic T-cell lymphoma (AITL) as well as non-AITL PTCL.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of KURA earnings conference call or presentation 7-May-19 8:30pm GMT

    Q1 2019 Kura Oncology Inc Earnings Call

  • Here’s What Hedge Funds Think About Kura Oncology, Inc. (KURA)
    Insider Monkey3 months ago

    Here’s What Hedge Funds Think About Kura Oncology, Inc. (KURA)

    Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]

  • Kura Oncology, Inc. (KURA) Q1 2019 Earnings Call Transcript
    Motley Fool3 months ago

    Kura Oncology, Inc. (KURA) Q1 2019 Earnings Call Transcript

    KURA earnings call for the period ending March 31, 2019.

  • Associated Press3 months ago

    Kura Oncology: 1Q Earnings Snapshot

    The San Diego-based company said it had a loss of 37 cents per share. The results beat Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss ...

  • GlobeNewswire3 months ago

    Kura Oncology Reports First Quarter 2019 Financial Results and Highlights Upcoming Milestones

    – Registration-directed trial of tipifarnib in HRAS mutant HNSCC continues on track – – Data from ongoing Phase 2 trial of tipifarnib in CXCL12-driven PTCL accepted for.

  • GlobeNewswire4 months ago

    Kura Oncology to Report First Quarter 2019 Financial Results

    SAN DIEGO, April 30, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology,.